96

UTILITY OF A MULTI-GENE METHYLATION PANEL TO RISK-STRATIFY PATIENTS WITH BARRETT’S ESOPHAGUS AFTER RADIOFREQUENCY ABLATION

Date
May 18, 2024

Introduction
Radiofrequency ablation (RFA) is effective to eradicate dysplastic Barrett’s esophagus (BE), however recurrence occurs in up to 25% of cases, typically at the gastro-esophageal junction (GEJ). We have shown that a multi-gene methylation panel (TFPI2, ZNF345 and ZNF569) can differentiate BE from normal GEJ mucosa. This study aims to determine whether this methylation panel correlates with dysplasia and can predict recurrence post-RFA.

Methods
This prospective cohort study (PROBAN) recruited patients with dysplastic BE, who achieved endoscopic remission post-RFA at two centers. Patients were eligible if they had 1) no endoscopic evidence of BE, 2) no suspicious dysplastic lesion at GEJ, and 3) no histological evidence of esophageal intestinal metaplasia (IM) at first post-RFA follow-up (GEJ IM allowed). Patients received endoscopy at baseline, 6, 12 and 24 months. Methylation score (Meth-score) was assessed by Methylight assay on random and narrow-band imaging targeted GEJ biopsies. The primary outcome was the correlation between Meth-score and histology of biopsies. The secondary outcome was the correlation of baseline methylation level with dysplastic recurrence at any time during follow-up.

Results
We included 124 patients who received 261 endoscopies. Mean age was 70.0 years (standard deviation [SD], 7.5 years). Mean pre-RFA maximum BE length was 4.6cm (SD, 3.1). The breakdown of pre-RFA BE histology were low-grade dysplasia (n=24, 19.5%), high-grade dysplasia (n=49, 39.8%) and intramucosal carcinoma (n=50, 40.7%). Overall, 12 patients (9.7%) developed dysplastic recurrence, all of which at the GEJ. On a per-endoscopy level, the median Meth-score of GEJ biopsies comparing patients with gastric metaplasia (GEJ-GM, n=185) intestinal metaplasia (GEJ-IM, n=63) and dysplasia (n=13) was 0%, 18.6%, and 50.0%, respectively, with a significance difference across the three histology groups (Kruskal-Wallis p<0.001) (Figure 1). When evaluating baseline (time 0) Meth-score and dysplastic recurrence at any time during follow-up, patients with dysplastic recurrence exhibited significantly higher median methylation levels compared to patients with no dysplasia (48.4% vs 0.5%, Mann-Whitney p<0.001) (Figure 2). A Meth-score cut-off of 0.73% had a sensitivity and a specificity for dysplastic recurrence of 92% and 55%, respectively.

Conclusion
A multi-gene methylation panel can discriminate patients with GM, IM and dysplasia on GEJ biopsies. Patients with stable histological remission had low baseline methylation levels. This biomarker panel can risk-stratify patients so that approximately half of patients with endoscopic remission post-RFA could benefit from relaxed surveillance intervals or early discharge in the appropriate clinical context, while those with high methylation levels could be offered retreatment of the GEJ before histological recurrence.
<b>Figure 1</b>. Median total methylation of individual endoscopies at any timepoint, and the corresponding histology comparing gastric metaplasia (GM) versus intestinal metaplasia (IM) versus dysplasia.

Figure 1. Median total methylation of individual endoscopies at any timepoint, and the corresponding histology comparing gastric metaplasia (GM) versus intestinal metaplasia (IM) versus dysplasia.

<b>Figure 2. </b>Median baseline methylation levels (time 0) and highest histology recorded at any time during follow-up (up to 24 months) comparing participants without dysplastic vs those with dysplastic recurrence.

Figure 2. Median baseline methylation levels (time 0) and highest histology recorded at any time during follow-up (up to 24 months) comparing participants without dysplastic vs those with dysplastic recurrence.


Tracks

Related Products

Thumbnail for MODELLING FROM A MULTICENTRE, PRAGMATIC, RANDOMISED CONTROLLED TRIAL IDENTIFIES THE TARGET SCREENING POPULATION AND EXPECTED YIELD FOR BARRETT’S ESOPHAGUS AND ESOPHAGEAL CANCER DIAGNOSES
MODELLING FROM A MULTICENTRE, PRAGMATIC, RANDOMISED CONTROLLED TRIAL IDENTIFIES THE TARGET SCREENING POPULATION AND EXPECTED YIELD FOR BARRETT’S ESOPHAGUS AND ESOPHAGEAL CANCER DIAGNOSES
Screening for Barrett’s esophagus (BE) could lead to earlier detection and improved survival of esophageal adenocarcinoma (EAC)…
Thumbnail for VIDEO-BASED COMPUTER AIDED DETECTION SYSTEM DETECTS BARRETT’S NEOPLASIA WITH HIGH ACCURACY DURING LIVE ENDOSCOPIC PROCEDURES: A MULTI-CENTER PILOT AND FEASIBILITY STUDY
VIDEO-BASED COMPUTER AIDED DETECTION SYSTEM DETECTS BARRETT’S NEOPLASIA WITH HIGH ACCURACY DURING LIVE ENDOSCOPIC PROCEDURES: A MULTI-CENTER PILOT AND FEASIBILITY STUDY
BACKGROUND: Using EsoCheck (EC), a non-endoscopic balloon device for sampling the distal esophagus, coupled with EsoGuard (EG), a DNA based testing screening for Barrett’s esophagus (BE), we have previously reported high sensitivity and specificity for detection of BE among patients with known BE c…
Thumbnail for DOMAIN-SPECIFIC PRETRAINING OF DEEP LEARNING SYSTEMS IN GASTROINTESTINAL ENDOSCOPY IMPROVES PERFORMANCE OVER CURRENT STATE-OF-THE-ART PRETRAINING METHODS
DOMAIN-SPECIFIC PRETRAINING OF DEEP LEARNING SYSTEMS IN GASTROINTESTINAL ENDOSCOPY IMPROVES PERFORMANCE OVER CURRENT STATE-OF-THE-ART PRETRAINING METHODS
For training deep learning algorithms in medical imaging, application-specific data is often scarce…
Thumbnail for A PROSPECTIVE, MULTI-INSTITUTIONAL STUDY REVEALS THE COMBINATION OF RNA ANALYSIS WITH DNA-BASED NEXT-GENERATION SEQUENCING (NGS) IMPROVES THE PREOPERATIVE CLASSIFICATION OF PANCREATIC CYSTS AND IDENTIFICATION OF ADVANCED NEOPLASIA
A PROSPECTIVE, MULTI-INSTITUTIONAL STUDY REVEALS THE COMBINATION OF RNA ANALYSIS WITH DNA-BASED NEXT-GENERATION SEQUENCING (NGS) IMPROVES THE PREOPERATIVE CLASSIFICATION OF PANCREATIC CYSTS AND IDENTIFICATION OF ADVANCED NEOPLASIA
BACKGROUND: As outlined by the Kyoto guidelines, targeted DNA-based NGS of pancreatic cyst fluid (PCF) is an important adjunct to the evaluation of pancreatic cyst patients…